SCHEMBL5135183

SCHEMBL5135183

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccccc1OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.39
C5AR1 P21730 1/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 3/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
BCHE P06276 3/20 0.38
ACHE P22303 3/20 0.38
DRD2 P14416 3/20 0.38
DRD3 P35462 3/20 0.38
ATP4A P20648 2/20 0.37
ATP4B P51164 2/20 0.37
MAPT P10636 1/20 0.37
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137485 0.97 C5AR1 (0.42) PDE4BC5AR1KDM4EMEN1RECQL
SCHEMBL5074328 0.95 DRD2 (0.38) C5AR1KDM4EPOLBTSHRALDH1A1
SCHEMBL5138086 0.93 C5AR1 (0.42) PDE4BC5AR1KDM4EMEN1RECQL
SCHEMBL5135036 0.92 KDM4E (0.38) PDE4BC5AR1KDM4EMEN1RECQL
SCHEMBL5135095 0.91 BCHE (0.47) C5AR1BCHEACHEMAPT
SCHEMBL5137575 0.90 C5AR1 (0.42) PDE4BC5AR1KDM4EMEN1RECQL
SCHEMBL5138021 0.89 C5AR1 (0.43) PDE4BC5AR1KDM4EMEN1RECQL
SCHEMBL5069962 0.88 BCHE (0.45) C5AR1TSHRBCHEACHE
SCHEMBL5135959 0.87 HDAC1 (0.36) C5AR1KDM4ETSHRALDH1A1CYP3A4
SCHEMBL5135633 0.87 C5AR1 (0.42) PDE4BC5AR1KDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed